Decoy Therapeutics Inc. Common Stock (DCOY) is a publicly traded the market company. As of May 21, 2026, DCOY trades at $5.56 with a market cap of $2.47M and a P/E ratio of 0.00. DCOY moved +3.49% today. Year to date, DCOY is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.32 to $16.92. Rallies surfaces DCOY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Decoy Therapeutics to Unveil AI Peptide Design Platform and New Preclinical Antiviral Data: Decoy Therapeutics will present on AI-driven de novo peptide design at two Boston conferences starting April 28 after partnering with Quantori to deploy a Google Cloud molecular simulation platform. Sessions include new preclinical data on its pan-coronavirus fusion inhibitor and a discovery-stage broad antiviral against influenza, COVID-19 and RSV.
| Metric | Value |
|---|---|
| Price | $5.56 |
| Market Cap | $2.47M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.92 |
| 52-Week Low | $4.32 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
DCOY analyst coverage data. Average price target: $0.00.